Search

everythinglearnresearchcommunity

for

Search:↓

Hair loss treatment should target dermal white adipose tissue (DWAT) to restore hair follicles. Potential remedies include tocopherol (vitamin E), botox, rosiglitazone, niacin, kojyl cinnamate esters, and ADP355.

Hair loss discussion includes Amplifica, a new treatment by Dr. Rassman and Dr. Plikus using molecules from hairy moles. No progress updates mentioned.

A user experienced increased shedding after adding KX-826 to their long-term finasteride and minoxidil regimen. Another user reported mild side effects from KX-826, such as stomach and testicle pain.

The conversation discusses the potential benefits and risks of using Methionine and Glycine for hair loss, with concerns about cancer risk if not balanced properly. The user seeks opinions on these amino acids for hair health and overall benefits.

The post discusses the potential of GT20029 in treating hair loss, questioning if it will replace finasteride or be used alongside existing treatments. A reply indicates that its role is still uncertain.

The user experienced hair regrowth using a routine of topical minoxidil, dutasteride, and microneedling, and is considering adding a peptide product for increased hair density. Other users suggest maintaining the current routine, monitoring heart health due to oral minoxidil, and considering cost-effective alternatives.

Peptides like GHK-Cu are discussed for hair regrowth, with mixed results; some users report no regrowth, while others notice thicker hair. Topical application is common, and proper sourcing and mixing are emphasized.

The user has been using topical finasteride and minoxidil for two years with decent regrowth and recently added microneedling to their routine. They are questioning if the small hairs observed are new regrowth from microneedling or just vellus or miniaturized hairs.

The conversation is about using PTD-DBM Peptide from Infiniwell for hair loss. The original poster is seeking feedback on its effectiveness.

Microneedling is effective for hair growth, especially when combined with finasteride and minoxidil, but concerns exist about potential long-term skin damage. Users report increased collagen and elastin deposition, but the long-term effects on the scalp remain uncertain.

A user reports significant hair density increase and new growth at the temples after two months of using finasteride, minoxidil, ketoconazole, dermarolling, MK-677, zinc, and vitamin D3, with shedding stopping a week ago. They recently added MK-677 to their regimen.

KX-826 shows promising results for hair growth with fewer side effects, offering an alternative to finasteride and minoxidil. Users discuss combining it with minoxidil, dermarolling, and Nizoral for improved results.

The conversation is about seeking information on GT20029 from Kintor Pharmaceutical as a potential hair loss cure and inquiring about experiences with CosmeaRNA.

KX-826 is undergoing trials for hair loss treatment, showing similar effectiveness between 0.5% and 1.0% dosages, with mild side effects compared to finasteride. Users discuss combining KX-826 with other treatments like minoxidil and clascoterone for better results.

The conversation discusses using minoxidil, finasteride, a dermastamp, and botanical oils like peppermint, rosemary, and pumpkin seed oil for hair growth. The user is considering using Alpha Infuse, which combines microneedling with plant oils, to enhance results.

New potential hair loss treatment uses molecules from hairy moles to stimulate follicle growth. Topical solution requires less frequent application, like Botox injections a few times per year.

The user experienced reduced hair loss using an online serum but found it too expensive and is seeking a vendor for ptd-dbm. They are also interested in KY19382 but are unable to find it.

The conversation discusses the mechanism of action of alfatradiol (17 alpha estradiol) in treating hair loss. It explores theories that it either inhibits 5 alpha reductase to prevent T->DHT conversion or aromatizes scalp T into 17-alpha-estradiol to save hair.

Amplifica's progress on Scube3 is unclear, with no recent updates. The conversation also mentions Minoxidil, finasteride, and RU58841 as hair loss treatments.

User seeks availability of Breezula and its delayed trials. Asks for success with similar topical antiandrogens like fluridil.

A user's experience with microneedling monotherapy and potential treatments such as finasteride, minoxidil, Stemoxydine, rosemary oil, peppermint oil, and RU58841 for reversing hair loss.

A drug that regrows body parts, but not hair, sparking debate on hair loss treatments. Discussions include the use of finasteride, dutasteride, and the potential for new methods to restore hair.

The conversation is about the progress of clinical trials for SCUBE3, a potential hair loss treatment. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

The conversation discusses the theory that scalp fibrosis contributes to male pattern baldness (MPB) by increasing DHT concentration, and mentions treatments like Minoxidil. The user seeks opinions on the theory and the effectiveness of scalp massages.

A user is experiencing facial bloating from low-dose topical finasteride due to high estradiol levels and is seeking advice on using DIM to manage this issue, including dosage and brand recommendations.

Melatonin's effect on aromatase expression is unclear, with studies showing both increases and decreases. Hormonal impacts are complex and inconsistent, similar to changing health advice on other substances.

SCUBE3 is a promising new molecule that can restart hair growth by reawakening dormant hair follicles. Users express skepticism about its availability timeline, with some hoping for release by 2026.

User tried oral finasteride, topical finasteride, topical dutasteride, and RU58841 but experienced side effects. They discuss upcoming treatments like clascoterone, pyrilutamide, gt20029, and KY19382 as potential options.

Stemson Therapeutics will start human trials for hair cloning in late 2025-2026. Product development is complete, and they are preparing for production and clinical trials.

The conversation discusses disappointment over only receiving a financial report from Cassiopea instead of trial results for Breezula/CB-03-01, a hair loss treatment. However, there is optimism as the company is advancing Breezula into Phase III trials for men, starting trials for women, and submitting an NDA for their acne product, Winlevi.